The size of the North America Neurotherapeutics Market is estimated to be growing at a promising rate between 2022 to 2027. North America has the highest share in the market due to top market players and significant technological advancements.
The growth of the neurotherapeutics market in the North American region is expected to be majorly driven by the factors such as an increase in the incidence of neurological disorders such as Alzheimer’s, Parkinson’s, neurological cancers across North America. Also, the rapid advancements in healthcare are expected to support the market growth.
Other factors such as rising awareness among the people about the various neurological disorders and the increasing healthcare expenditure are fuelling the market growth. In addition, the growing geriatric population is one of the significant growth contributors of the Neurotherapeutics market because the senior population is vulnerable to brain disorders; therefore, the life expectancy of the people is expected to boost the market growth.
On the other hand, the factors such as the growing population, changing lifestyles, associated congenital health problems, genetic disorders, and other traumas significantly influence market growth. The increasing population and the life expectancy of the people are expected to drive market growth. DBS is becoming more popular as a therapeutic option for drug-resistant movement disorders such as Parkinson's disease, dystonia, and tremor. Deep brain stimulation involves implanting a device that stimulates the parts of the brain that govern movement. The increasing prevalence of neurological illnesses that result in paralysis or impairment is one of the primary reasons driving market expansion.
Increasing investments and funding by the key market players and government in research and development activities are expected to provide lucrative growth opportunities for market growth. To gain a competitive advantage over the marketplace, the key players in the region are adopting various market strategies such as partnerships, mergers, and acquisitions. These strategies also strengthen the regional market growth. Furthermore, with favorable reimbursement policies, the FDA has approved the insertion of a brain implant to treat tremor symptoms. These factors are also expected to drive the neurological movement disorders market forward.
However, the presence of a complex regulatory framework and lack of proper reimbursement policies in some of the areas of the North American region is expected to restrain the market growth.
This research report on the North American neurotherapeutics market has been segmented and sub-segmented into the following categories.
By Distribution channels:
Regionally, the North American market dominated the global neurotherapeutics market in 2020, and it is anticipated to witness a significant share during the forecast period. The regional market growth is projected to be fuelled by the availability of advanced healthcare infrastructure, high healthcare spending, and favorable reimbursement policies. In addition, the presence of the largest economies such as the United States and Canada are significantly contributing to the North American regional market growth.
The United States accounted for the largest share of the market, and it is most likely to continue its dominance throughout the forecast period. The proliferation of neurological disorders, a better understanding of the nature of neurological diseases, technological advancements in healthcare sectors, and high healthcare spending are propelling the market growth.
The Canadian market is projected to record a significant share during the forecast period. Increasing investments, supportive government policies, improving the healthcare sector, and increasing prevalence of neurological disorders are surging the market growth.
KEY MARKET PLAYERS:
Companies operating in the North America Neurotherapeutics Market are Abbott Laboratories, Inc., Becton, Novartis AG, Dickinson and Company, Pfizer, Inc., Johnson & Johnson, Biogen, Inc., GlaxoSmithKline, Inc., AstraZeneca plc, Sanofi-Aventis, Spiegelberg, Stryker, Covidien, Medtronic, GE healthcare, and Merck & Co.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1.2 Neurologic Drugs
184.108.40.206 Oral Administration
5.1.3 Neurologic Devices
220.127.116.11 Electroconvulsive Therapy (ECT)
18.104.22.168 Vagus Nerve Stimulation (VNS)
22.214.171.124 Transcranial magnetic stimulation
126.96.36.199 Deep Brain Stimulator
5.1.4 Y-o-Y Growth Analysis, By Product
5.1.5 Market Attractiveness Analysis, By Product
5.1.6 Market Share Analysis, By Product
5.2.2 Central Nervous system disorder
5.2.3 Peripheral Nervous system disorder
5.2.4 Autonomous Nervous system disorder
5.2.5 Y-o-Y Growth Analysis, By Type
5.2.6 Market Attractiveness Analysis, By Type
5.2.7 Market Share Analysis, By Type
5.3 Distribution Channels
5.3.3 Neurotherapeutic center
5.3.4 Clinical Research organisations
5.3.6 Y-o-Y Growth Analysis, By Application
5.3.7 Market Attractiveness Analysis, By Application
5.3.8 Market Share Analysis, By Application
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
188.8.131.52 By Geographical Area
184.108.40.206 By Treatment
220.127.116.11 By Disorders
18.104.22.168 By Distribution Channels
6.1.4 Market Attractiveness Analysis
22.214.171.124 By Geographical Area
126.96.36.199 By Treatment
188.8.131.52 By Disorders
184.108.40.206 By Distributional Channels
6.1.5 Market Share Analysis
220.127.116.11 By Geographical Area
18.104.22.168 By Treatment
22.214.171.124 By Disorders
126.96.36.199 By Distribution channels
6.2 United States
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Abbott Laboratories
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.3 Novartis AG
8.4 Dickinson and Company
8.6 Johnson & Johnson
8.10 Sanofi Aventis
8.14 GE Health Care
8.15 Merck & Co
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.